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Summary: The interference of immunoglobulins in the radioimmunoassay (RIA) of human ß-endorphin was
investigated. Human IgM showed no cross-reactivity. Human IgA showed a weak cross-reaction, but the
dilution curve of IgA did not show parallelism with the standard curve of ß-endorphin, thus indicating its
antigenic difference. The dilution curves of human IgG showed 0.18% displacement with respect to the human
ß-endorphin standard curve, with good parallelism. Moreover, five patients with multiple myeloma of the
IgG type showed falsely elevated ß-endorphin levels. We investigated the possibility that certain IgGs may be
responsible for the displacement of [125I] ß-endorphin in the ß-endorphin kit. The apparent ß-endorphin level
of plasma from multiple myeloma patients was markedly decreased after affinity chromatography of the
serum on protein A-Sepharose.
In another 3 patients with multiple myeloma, we examined IgG interference by measuring the ß-endorphin
levels in their lyophilized IgG diluted with saline. The results demonstrated high values of 20.2, 25.5 and
21.2 pmol/1 respectively, also showing good parallelism. These immunological parallels to human ß-endorphin
verify that a part of the amino acid sequence of human IgG is similar to that of human ß-endorphin.
Consequently, in the measurement of ß-endorphin with polyclonal antibody, the results may sometimes be
spuriously high due to cross-reaction with IgG, e. g. in patients with IgG myeloma. To avoid IgG interference,
a specific monoclonal antibody to synthetic ß-endorphin should be used rather than polyclonal antibodies.
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No information concerning these questions has hith-
erto been reported. We therefore investigated the in-
fluence of human IgG on the radioimmunoassay for
human pituitary hormones, including ß-endorphin in
order to elucidate possible existing homologies in the
amino acid sequences of these physiologically unre-
lated substances.
Normal subjects and patients
Normal ß-endorphin values were determined in 82 normal
healthy volunteers (43 males; 49 females; aged 18 — 65) whose
blood was collected between 0800 and 0900. The blood samples
(5 — 10 ml) were collected in plastic tubes by venipuncture
containing 2 g/1 EDTA; centrifuged within 15 min, the plasma
separated and immediately frozen at — 20 °C. Six of the vol-
unteers were given metyrapone, 2.0 g orally at 9 a. m., with
blood samples drawn immediately beforehand and after 6 h
and 8 h. From the volunteer group blood samples for ß-endor-
phin, corticotropin and cortisol were obtained from 6 subjects
at 11 p.m., followed by the administration of 1.0 mg of dexa-
methasone orally. At 6 a. m. and 8 a. m. further blood samples
were obtained. Six more normal subjects underwent an insulin
tolerance test (monocomponent insulin 0.1 U/kg). During this
test blood samples were taken via an intravenous cannula at
-30, -15, 0, 15, 30, 60, 90, and 120 min and assayed for
glucose, corticotropin, ß-endorphin, cortisol and insulin.
Five patients with pituitary corticotropin-dependent Cushing's
disease who had been bilaterally adrenalectomized and five
patients with Addison's disease receiving corticosteroid replace-
ment therapy were studied. Replacement therapy was omitted
on the morning of the study; venous blood samples were taken
at 0900 h and thereafter at 30 min intervals for 3 h, and were
assayed for corticotropin, ß-endorphin and cortisol. Five pa-
tients with multiple myeloma of the IgG type (3 Lambda, 2
Kappa) had plasma taken for ß-endorphin assay. These samples
were assayed with and without affinity chromatography on
staphylococcal protein A-Sepharose.
Materials and Methods
Concentrations of immunoreactive ß-endorphin were deter-
mined by means of a commercial radioimmunoassay kit devel-
oped by the New England Nuclear Company, Boston, MA,
USA, with antiserum from rabbits prepared against synthetic
human ß-endorphin (synthesized by the Peptide Division of the
Beckman Company, FRG). Synthetic ß-endorphin was labelled
with Na125I using chloramine T. The specific activity of [125I]ß-
endorphin ranged from 56.1 to 83.6 TBq/mmol. The assay was
performed according to the following protocol. Briefly, 0.1 ml
specimen was used. Synthetic human ß-endorphin served as a
standard. The antiserum to ß-endorphin was used at a final
dilution of 1:8000. Separation of the bound, from free antigen,
was achieved by adsorption onto activated charcoal. The spec-
ificity of the ß-endorphin antiserum was 50% for ß-lipotropic
hormone (ß-lipotropin), less than 0.01% for oc-endorphin and
oc-melanocyte stimulating hormone ( -melanotropin), and less
than 0.004% for leu-enkephalin and met-enkephalin. The min-
imal detectable dose was 5.0 pmol/1. The intra- and interassay
variation were 5.6% and 12% respectively. To ensure the ac-
curacy of our RIA in the determination of human plasma ß-
endorphin levels, we performed dexamethasone supression
tests, insulin hypoglycaemia tests and metyrapone tests on
normal healthy subjects; the results were in agreement with
previously reported values for ß-endorphin in these tests. In
our laboratory the ß-endorphin levels ranged from 5 — 30
pmol/1.
Highly purified human IgG was obtained from Cappel Labs
West Chester, PA, USA, (lot no. 29153), Kabi Co. (lot no.
58803), Sweden, and Miles Labs, Indiana, USA (lot no. 8376);
human IgA from Miles Labs (lot no. 21277) and human IgM
from Miles Labs (lot no. 9675). Human immunoglobulins (IgG,
IgA and IgM) were measured by laser nephelometry (Hoechst
Co. FRG). The M-protein types and light chain types were
identified by Beckman Paragon Immunofixation Electropho-
resis (Beckman, Brea, CA, USA). For affinity chromatography
of the samples on Protein A-Sepharose, we used the Immuno-
pure IgG Purification Kit (Pierce Chemical Co., USA) accord-
ing to the manufacturer's instructions.
Results
Plasma ß-endorphin concentrations
Table 1 shows the circulating plasma ß-endorphin
levels in 82 healthy normal subjects, 5 bilaterally
adrenalectomized patients with Cushing's disease and
5 patients with Addison's disease. During the dexa-
methasone suppression tests the plasma ß-endorphin
levels fell in each subject and rose during the insulin-
induced hypoglycaemia and metyrapone tests. All the
patients with Cushing's disease and Addison's disease
had elevated plasma ß-endorphin and corticotropin
concentrations.
Tab. 1. Concentrations (mean ± SD) of plasma ß-endorphin (pmol/1) in normal subjects, patients with bilaterally adrenalectomized
Cushing's disease and Addison's disease.
* P < 0.01,
Subjects
Normal males
Normal females
Normal males
Normal males
Gushing^ disease
Addison's disease
** P < 0
n
43
49
6
6
5
5
.001
Basal level Post metyrapone
7.9 + 0.9
7.7 + 1.1
7.7 + 0.8 26.1 + 2.1* (a)
7.8 + 1.0
68.2 + 5.6** (b)
91.5 ± 11.2** (b)
Post dexamethasone Post insulin
hypoglycaemia
<5.0 ~ 6.1* (a)
18.2 ± 3.2* (a)
Statistical analysis: (a) Paired t test (basal level vs post drug administration)
(b) Student t test
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Tab. 2. Plasma ß-endorphin levels and related data in 5 patients with multiple myeloma
Pa- Sex
tient
No.
1
2 o
3 9
4 3
5 3
Reference
Age
(a)
37
40
44
67
70
ranges
Protein concentrations (g/1)
To-
tal
pro-
tein
113
86
101
112
102
66-
81
Al-
bu-
min
36.6
39.8
33.8
35.8
34.1
39-
49
al- a2-
globulins
1.6
2.6
6.6
6.7
1.8
1.0-
3.5
4.6
5.2
11.6
14.6
4.4
5.5-
11.8
ß-
4.6
3.9
8.1
4.5
4.5
4.3-
9.0
Y-
65.5
34.6
40.9
50.4
57.2
5.5-
14.1
Immunoglobulin concen-
trations (mg/1)
IgG
69100
36300
49250
53200
61150
13000-
17740
IgM
460
620
390
420
510
600-
1480
IgA
680
1500
980
720
950
1780-
3550
Light
chain
type
ß-Endorphin con-
centrations (pmol/1)
without with
purification by pro-
tein A-Sepharose
Kappa
Lambda
Lambda
Lambda
Kappa
23.4
16.3
18.1
15.2
19.4
*18.5 ±
1.4
9.1
8.8
8.2
5.2
5.1
7.3 +
0.9
p < 0.01
Table 2 shows the ß-endorphin levels in patients with
multiple myeloma of the IgG type. All the patients
showed high plasma ß-endorphin levels but within the
normal range, but then showed a marked decline after
affinity chromatography on staphylococcal protein A-
Sepharose, which suggests IgG interference.
The effect of human IgG, A, M, on the ß-
endorphin rad io immunoassay
The dilution curve of human IgA and IgM did not
show parallelism with the human ß-endorphin stan-
dard curve, suggesting the IgA and IgM do not pos-
sess sequence homologies to ß-endorphin. In contrast,
commercial human IgG causes a significant displace-
ment of labelled ß-endorphin, with good parallelism
(fig. 1); i. e. the dilution curves of IgG from Miles
Labs, Cappel Labs and Kabi company showed 0.20%,
0.18% and 0.16% cross-reactivity, respectively, with
the standard curve for ß-endorphin, thus indicating
1.00
^0.50
Human IgM
Human IgA
Human ß-endorphin
102 103 104 105 106
Peptide concentration [ng/l]
107
Fig. 1. Inhibition curves associated with various human im-
munoglobulins in the human ß-endorphin radioimmu-
noassay.
immunological identity. After affinity chromatogra-
phy of the serum on staphylococcal protein A-Se-
pharose (13), no immunological cross-reactivity was
observed.
The effect of IgG on human pi tu i tary hor-
mone radio immunoassays
No immunological effect of IgG was found in the
radioimmunoassays for lutropin, follitropin, thyrotro-
pin, prolactin or somatotropin, indicating that there
is no immunological similarity between the amino acid
sequences of these hormones and that of IgG.
Discussion
The circulating human ß-endorphin levels were
checked by radioimmunoassay and were found to be
5 — 30 pmol/1. Moreover, the ß-endorphin response in
the dexamethasone suppression test, insulin hypo-
glycaemia test and metyrapone test showed results
corresponding to those previously reported (14 — 17).
In 1980, Julliard et al. (12) discovered structual
homologies between ß-endorphin and IgG using
a computer program. They synthesized a fragment
of human IgG heavy chain 363 to 379
(VSLTCLVKGFYPSDIAV) by solid-phase tech-
niques and reported that this fragment showed 0.18
percent displacement of the human ß-endorphin
tracer, with good parallelism. Our present study con-
curs with Julliard s finding (12).
This result suggested that spuriously high ß-endorphin
levels may be obtained in patients with high -glob-
ulinaemia. Therefore a preliminary examination of
three patients with IgG myeloma was carried out.
Their lyophilized IgG, diluted with saline to a con-
centration of 177, 185, 162 g/1, indeed showed high
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ß-endorphin values, i.e. 20.2, 25.5, 21.2 pmol/1, re-
spectively, but showed negligible ß-endorphin levels
after the removal of IgG proteins by affinity
chromatography on protein A-Sepharose. It is there-
fore concluded that the pseudo-ß-endorphin activity
of human plasma proteins is essentially due to the
effect of IgG per se. To cross check the accuracy of
these results we pre-added ß-endorphin to the IgG
solution from the same patients and carried out affin-
ity chromatography. The subsequent recovery of ß-
endorphin was 95.6 ± 2.3% (Mean ± SE), thus dem-
onstrating that there were no changes in concentration
of ß-endorphin in the IgG solution. This study clearly
excludes the possibility that the ß-endorphin is non-
covalently linked to IgG. Moreover, in order to con-
firm our hypothesis we performed further experiments
using the plasma from five other patients suffering
from IgG myeloma. We studied the ß-endorphin levels
before and after staphylococcal affinity chromatog-
raphy on protein A-Sepharose. As shown in table 2
the plasma ß-endorphin levels were elevated before
and markedly decreased after. These results clearly
indicate IgG interference in the human ß-endorphin
radioimmunoassay.
Julliard et al. (12) reported that their studies had led
to the unexpected recognition of several homologies
in the amino acid sequences of two physiologically
unrelated substances, such as pituitary hormone (ß-
endorphin and corticotropin) and the constant chain
of an IgG. We therefore conducted a further study
on the effect of IgG proteins on the radioimmun o-
assays of several pituitary hormones, in order to in-
vestigate the possibility of other unexpected relation-
ships. In our studies of peptide hormones, no immu-
nological similarities to IgG were found. However,
the observation made by Julliard et al. (12) does seem
important, and there may be other cases of substances
arising from the same origin, which previously have
been thought to be unrelated. Very recently a study
by Campino et al. (18) described that immunoreactive
human growth hormone, in a patient with acromeg-
aly, is in fact IgG. Additional studies are expected.
Through our studies, it has become clear that to avoid
IgG interference a specific monoclonal antibody
which recognises the epitope of ß-endorphin is pref-
erable to using polyclonal antibodies raised in ani-
mals. The use of such a specific monoclonal antibody
would avoid the spuriously high results for ß-endor-
phin in patients with high IgG levels. Recently
Voellmy et al. (19) reported a two-site immunoradio-
metric assay for human ß-endorphin using a poly-
clonal rabbit anti-ß-endorphin antibody and an 125I-
labeled monoclonal mouse antibody 3-E7, which
binds to the N-terminal region of ß-endorphin. If no
IgG effect is demonstrated with this newly developed
monoclonal antibody method, we can anticipate
greater accuracy and reliability in the determination
of ß-endorphin concentrations.
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